Synopsis
Novo Nordisk, the most valuable pharmaceutical company in the world, turned 100 last year. While it is largely known for its insulins, its anti-obesity drugs are making waves of late. Maziar Mike Doustdar, executive vice-president, international operations at Novo Nordisk tells ET Prime the beliefs that distinguish the company.
Danish pharmaceutical company Novo Nordisk celebrated its centenary last year. Yet, it has mostly kept a low profile. Known for a spectrum of insulins, the company has retained a strong grip on its market share. But a big surprise was in store beyond insulins. After two decades of research by its scientists, Novo Nordisk landed a remarkable feat. First Ozempic and then Wegovy, the two drugs were found very effective in cutting obesity. The
- FONT SIZE
AbcSmall
AbcMedium
AbcLarge
Uh-oh! This is an exclusive story available for selected readers only.
Worry not. You’re just a step away.
Why ?
Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors
Stock analysis. Market Research. Industry Trends on 4000+ Stocks
Clean experience with
Minimal Ads
Comment & Engage with ET Prime community 
Exclusive invites to Virtual Events with Industry Leaders 
A trusted team of Journalists & Analysts who can best filter signal from noise 
Get 1 Year Complimentary Subscription of TOI+ worth Rs.799/-
